// App-Quantinova.ai

2535 : SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancerPFS ratio from patients who crossed-over.

Researchers

Presenter

  • Christophe Le Tourneau

Principal Investigators

  • Maud Kamal

  • Cecile Mauborgne

  • Fabrice Mulot

  • Jean-Pierre Delord

  • Anthony Goncalves

  • Celine Gavoille

  • Coraline Dubot

  • Nicolas Isambert

  • Mario Campone

  • Olivier Tredan

  • Francesco Ricci

  • Marie Alt

  • Delphine Loirat

  • Marie-Paule Sablin

  • Xavier Paoletti

  • Vincent Servois

  • Lisa Belin

Medical Centers

  • Institut Curie, Paris Cedex, France

  • Institut Claudius Regaud, Toulouse, France

  • Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

  • Institut de Cancerologie de Lorraine, Departement d'Oncologie Medicale, Nancy, France

  • Hopital Rene Huguenin/Institut Curie, Saint-Cloud, France

  • Center Georges-Francois Leclerc, Dijon, France

  • Cancer Institute of the West (ICO), Centre Rene Gauducheau, Medical Oncology Department, Saint-Herblain, France

  • Departement d'Oncologie Medicale, Centre Leon Berard, Lyon, France

  • Oncology Department, Institut Curie, Paris, France

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • Positive

Study Design

  • Randomized

  • Cross Over

Phase

  • II

Study Id's

  • NCT01771458

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved